1. The Trinity of Targeting

Tissue specificity is rarely achieved by the promoter alone. It is a “triad” of design choices:

• Promoter: The internal genetic instructions (e.g., hSyn for neurons).
• Serotype: The external protein shell. For example, AAV9 crosses the blood-brain barrier, whereas AAV8 is highly “hepatotropic” (liver-loving).
• Route of Delivery: Direct injection into the sub-retinal space or the striatum bypasses systemic barriers and reduces off-target effects in the liver or spleen.

2. Overcoming the AAV Size Limit

The strict 4.7 kb packaging limit (from ITR to ITR) is the biggest hurdle in AAV design. If your promoter is too large, you must use:

• Truncated Promoters: Removing non-essential distal regions while keeping core transcription factor binding sites (e.g., the 681 bp gfaABC1D vs. the 2.2 kb GFAP).
• Synthetic Hybrids: Combining a tiny, potent enhancer with a minimal promoter (e.g., the ApoE-hAAT hybrid for the liver).

3. Boosting Strength: Enhancers and Post-Transcriptional Elements

To compensate for the relative “weakness” of tissue-specific promoters compared to viral ones (like CMV), researchers add:

• WPRE (Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element): Placed before the polyA tail, it significantly increases transgene expression by enhancing mRNA stability.
• Introns (e.g., chimeric introns): Including an intron in the 5′ UTR can facilitate the nuclear export of mRNA.
• PolyA Tails: Using a strong polyA (like bGH polyA) ensures efficient termination and polyadenylation, preventing read-through and gene silencing.

4. Avoiding “Leakiness”

Even “tissue-specific” promoters can sometimes be active in the liver (the body’s primary viral filter). To ensure absolute specificity, designers often incorporate microRNA (miRNA) binding sites (e.g., miR-122 for liver or miR-142 for immune cells) in the 3′ UTR. If the virus enters a non-target cell, the endogenous miRNA will recognize the site and degrade the transgene mRNA.

Recommended Promoter–Serotype Pairs for AAV Vectors

CNS / Brain

• hSyn + AAV9 / AAV-PHP.eB → Pan-neuronal (in vivo, rodents)
• CaMKIIα + AAV9 / AAV1 → Excitatory neurons
• GFAP + AAV9 / AAV5 → Astrocytes
• MBP / PLP1 + AAV9 → Oligodendrocytes

Liver

• TBG + AAV8 / AAV-LK03 → Hepatocytes (gold standard)
• Albumin + AAV8 → Long-term liver expression
• ApoE-hAAT + AAV8 → High-expression liver targeting

Muscle

• tMCK + AAV9 / AAV1 → Skeletal muscle
• Desmin + AAV9 → Muscle-restricted
• α-Actin + AAV1 → Skeletal muscle

Heart

• cTnT + AAV9 → Cardiomyocytes (high specificity)
• α-MHC + AAV9 → Cardiac muscle
• MLC2v + AAV9 → Ventricular myocytes

Eye / Retina

• RHO + AAV8 / AAV2 → Rod photoreceptors
• GRK1 + AAV8 → Rods & cones
• BEST1 / RPE65 + AAV2 → RPE cells

Pancreas

• Insulin (RIP) + AAV8 → β cells
• PDX1 + AAV8 → Pancreatic progenitors

Endothelium

• Tie2 + AAV9
• VE-cadherin + AAV9

Promoter Strength vs Specificity (Quick Guide)

Promoter Type	Strength	Specificity	Typical Use
CMV	Very High	None	In vitro / screening
CAG	Very High	Broad	In vivo general
Tissue-specific	Moderate	High	Functional studies, therapy
Mini / Truncated	Moderate	High	Size-limited AAV

---

---

Clinical & Design Notes (Important)

• Tissue specificity ≠ promoter alone
  → Serotype + dose + route are equally critical
• Truncated promoters are often preferred for clinical AAV
• Avoid CMV in long-term in vivo studies (silencing risk)
• Add WPRE / intron to boost expression if size allows